CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) ("Takeda") today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The trial evaluated the effect of single-agent oral NINLARO (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation. TOURMALINE-MM4 is the first industry sponsored Phase 3 trial to explore the concept of switch maintenance, the use of medicines not included in initial induction therapy, in this setting. NINLARO is currently not approved for this specific use.
We are very encouraged by the results of the TOURMALINE-MM4 trial and continue our forward momentum in developing maintenance options for multiple myeloma patients. Importantly, this is the third positive Phase 3 readout from the TOURMALINE clinical trial program, said Phil Rowlands, Ph.D., Head, Oncology Therapeutic Area Unit, Takeda. We remain committed to bringing this convenient and well-tolerated treatment option to patients.
The safety profile of NINLARO in the maintenance setting was consistent with previously reported results of single-agent NINLARO use, and there were no new safety signals identified in TOURMALINE-MM4.
Full data results will be submitted for presentation at an upcoming medical meeting.
About the TOURMALINE-MM4 Trial
TOURMALINE-MM4 is a randomized, placebo-controlled, double-blind Phase 3 study of 706 patients, designed to determine the effect of single-agent oral NINLAROTM (ixazomib) maintenance therapy on progression-free survival (PFS), compared to placebo, in adult patients newly diagnosed with multiple myeloma not treated with stem cell transplantation, who have completed 6-12 months of initial therapy and achieved a partial response or better. For additional information, please visit https://clinicaltrials.gov/ct2/show/NCT02312258.
About Multiple Myeloma
Multiple myeloma is a life-threatening rare blood cancer that arises from the plasma cells, a type of white blood cell that is made in the bone marrow. These plasma cells become abnormal, multiply and release a type of antibody known as a paraprotein, which causes symptoms of the disease, including bone pain, frequent or recurring infections and fatigue, a symptom of anemia. These malignant plasma cells have the potential to affect many bones in the body and can cause a number of serious health problems affecting the bones, immune system, kidneys and red blood cell count. The typical multiple myeloma disease course includes periods of symptomatic myeloma followed by periods of remission. Nearly 230,000 people around the world live with multiple myeloma, with approximately 114,000 new cases diagnosed globally each year.
About NINLAROTM (ixazomib) capsules
NINLARO (ixazomib) is an oral proteasome inhibitor which is being studied across the continuum of multiple myeloma treatment settings. NINLARO was first approved by the U.S. Food and Drug Administration (FDA) in November 2015 and is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is currently approved in more than 60 countries, including the United States, Japan and in the European Union, with more than 10 regulatory filings currently under review. It was the first oral proteasome inhibitor to enter Phase 3 clinical trials and to receive approval.
The comprehensive ixazomib clinical development program, TOURMALINE, includes several ongoing pivotal trials, which together are investigating major multiple myeloma patient populations:
In addition to the TOURMALINE program, ixazomib is being evaluated in multiple therapeutic combinations for various patient populations in investigator initiated studies globally.
NINLAROTM (ixazomib) capsules: Global Important Safety Information
SPECIAL WARNINGS AND PRECAUTIONSThrombocytopenia has been reported with NINLARO (28% vs. 14% in the NINLARO and placebo regimens, respectively) with platelet nadirs typically occurring between Days 14-21 of each 28-day cycle and recovery to baseline by the start of the next cycle. It did not result in an increase in hemorrhagic events or platelet transfusions. Monitor platelet counts at least monthly during treatment with NINLARO and consider more frequent monitoring during the first three cycles. Manage with dose modifications and platelet transfusions as per standard medical guidelines.
Gastrointestinal toxicities have been reported in the NINLARO and placebo regimens respectively, such as diarrhea (42% vs. 36%), constipation (34% vs. 25%), nausea (26% vs. 21%), and vomiting (22% vs. 11%), occasionally requiring use of antiemetic and anti-diarrheal medications, and supportive care.
Peripheral neuropathy was reported with NINLARO (28% vs. 21% in the NINLARO and placebo regimens, respectively). The most commonly reported reaction was peripheral sensory neuropathy (19% and 14% in the NINLARO and placebo regimens, respectively). Peripheral motor neuropathy was not commonly reported in either regimen (< 1%). Monitor patients for symptoms of peripheral neuropathy and adjust dosing as needed.
Peripheral edema was reported with NINLARO (25% vs. 18% in the NINLARO and placebo regimens, respectively). Evaluate patients for underlying causes and provide supportive care, as necessary. Adjust the dose of dexamethasone per its prescribing information or the dose of NINLARO for severe symptoms.
Cutaneous reactions occurred in 19% of patients in the NINLARO regimen compared to 11% of patients in the placebo regimen. The most common type of rash reported in both regimens was maculo-papular and macular rash. Manage rash with supportive care, dose modification or discontinuation.
Hepatotoxicity, drug-induced liver injury, hepatocellular injury, hepatic steatosis, and hepatitis cholestatic have been uncommonly reported with NINLARO. Monitor hepatic enzymes regularly and adjust dose for Grade 3 or 4 symptoms.
Pregnancy- NINLARO can cause fetal harm. Advise male and female patients of reproductive potential to use contraceptive measures during treatment and for an additional 90 days after the final dose of NINLARO. Women of childbearing potential should avoid becoming pregnant while taking NINLARO due to potential hazard to the fetus. Women using hormonal contraceptives should use an additional barrier method of contraception.
Lactation- It is not known whether NINLARO or its metabolites are excreted in human milk. There could be potential adverse events in nursing infants and therefore breastfeeding should be discontinued.
SPECIAL PATIENT POPULATIONSHepatic Impairment: Reduce the NINLARO starting dose to 3 mg in patients with moderate or severe hepatic impairment.
Renal Impairment: Reduce the NINLARO starting dose to 3 mg in patients with severe renal impairment or end-stage renal disease (ESRD) requiring dialysis. NINLARO is not dialyzable and, therefore, can be administered without regard to the timing of dialysis.
DRUG INTERACTIONSCo-administration of strong CYP3A inducers with NINLARO is not recommended.
ADVERSE REACTIONSThe most frequently reported adverse reactions ( 20%) in the NINLARO regimen, and greater than in the placebo regimen, were diarrhea (42% vs. 36%), constipation (34% vs. 25%), thrombocytopenia (28% vs. 14%), peripheral neuropathy (28% vs. 21%), nausea (26% vs. 21%), peripheral edema (25% vs. 18%), vomiting (22% vs. 11%), and back pain (21% vs. 16%). Serious adverse reactions reported in 2% of patients included thrombocytopenia (2%) and diarrhea (2%). For each adverse reaction, one or more of the three drugs was discontinued in 1% of patients in the NINLARO regimen.
For European Union Summary of Product Characteristics: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003844/WC500217620.pdf For US Prescribing Information: https://www.ninlarohcp.com/pdf/prescribing-information.pdf For Canada Product Monograph: http://www.takedacanada.com/ninlaropm
About Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.
Important NoticeFor the purposes of this notice, press release means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (Takeda) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, Takeda is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words we, us and our are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
Forward-Looking StatementsThis press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takedas future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as targets, plans, believes, hopes, continues, expects, aims, intends, ensures, will, may, should, would, could anticipates, estimates, projects or similar expressions or the negative thereof. Forward-looking statements in this document are based on Takedas estimates and assumptions only as of the date hereof. Such forward-looking statements do not represent any guarantee by Takeda or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding Takedas global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the timing and impact of post-merger integration efforts with acquired companies; and the ability to divest assets that are not core to Takedas operations and the timing of any such divestment(s), any of which may cause Takedas actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect Takedas results, performance, achievements, or financial position, see Item 3. Key InformationD. Risk Factors in Takedas most recent Annual Report on Form 20-F and Takedas other reports filed with the U.S. Securities and Exchange Commission, available on Takedas website at: https://www.takeda.com/investors/reports/sec-filings/ or at http://www.sec.gov. Future results, performance, achievements or financial position of Takeda could differ materially from those expressed in or implied by the forward-looking statements. Persons receiving this press release should not rely unduly on any forward-looking statements. Takeda undertakes no obligation to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results of Takeda in this press release may not be indicative of, and are not an estimate, forecast or projection of Takedas future results.
- What we learn from a fish that can change sex in just 10 days - The Conversation AU - January 26th, 2020
- Stem cells: Sources, types, and uses - January 25th, 2020
- If you want to ban fetal tissue research, sign a pledge to refuse its benefits - The Coloradoan - January 25th, 2020
- Tiny organs grown from snake glands produce real venom - Science Magazine - January 23rd, 2020
- Asymmetrex Partners in Manufacturing USA Institute January 23, 2020The Advanced Regenerative Manufacturing Institute - PR Web - January 23rd, 2020
- Genmab Announces European Marketing Authorization for DARZALEX (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontli... - January 23rd, 2020
- Video: In 40 years, babies could be made in the lab from skin cells - Genetic Literacy Project - January 21st, 2020
- Here's What Meat-Eaters Really Think of Veganism, According to a New Study - ScienceAlert - January 21st, 2020
- What meat eaters really think about veganism new research - The Conversation UK - January 21st, 2020
- Mutations in Donor Stem Cells Could Harm the Health of Patients with Cancer, Study Finds - Curetoday.com - January 18th, 2020
- Role of wearable sensors in the early diagnosis of Graft Versus Host Disease - Verdict Medical Devices - Medical Device Network - January 18th, 2020
- Stem Cell Therapy for Dogs and Cats Is Innovative at Stafford Veterinary Hospital - By MARIA SCANDALE - The SandPaper - January 17th, 2020
- World-first Genomic Analysis of Puberty Provides Insights Into Cancer and Infertility - Technology Networks - January 13th, 2020
- Stem Cell Assay Market is estimated to witness the highest growth during the forecast period 2017 2025 - Pro News Time - January 13th, 2020
- Bionic Vision Technologies Announces Interim Pilot Study Results of the BVT Bionic Eye System Designed to Help the Blind Achieve Greater Mobility and... - January 13th, 2020
- Unlocking The Secrets Of DNA Help Researchers Understand How to Slow Aging - YouAreUNLTD - January 12th, 2020
- BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week - Yahoo Finance - January 11th, 2020
- Mesenchymal Stem Cells Market to Perceive Substantial Growth During 2019 to 2027 | Lonza, Thermo Fisher, Bio-Techne, Miltenyi Biotec, PromoCell GmbH,... - January 11th, 2020
- Understanding the developmental conditions of the human spine - Tech Explorist - January 11th, 2020
- BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week - GlobeNewswire - January 8th, 2020
- A New "Census" of the Zebrafish Brain - Technology Networks - January 8th, 2020
- Cynata Therapeutics (ASX:CYP) receives R&D tax incentive refund of more than $1.8M - The Market Herald - January 8th, 2020
- Contemporary Bone Alleviates Mechanisms Have Prospective Therapeutic Applications - MENAFN.COM - January 8th, 2020
- New Treatment Approved in Canada for Most Common Type of Leukemia - Canada NewsWire - January 8th, 2020
- New protocol could signal shift in bone regenerative medicine - Yahoo Finance - January 6th, 2020
- Researchers at Baylor College of Medicine Discover How to Improve Bone Repair - Gilmore Health News - January 6th, 2020
- Stem Cells Market in The Region Is Anticipated To Expand At a CAGR of 13.8% During the Period from 2017 to 2025 - Market Research Sheets - January 3rd, 2020
- Deficiency of TRPM2 leads to embryonic neurogenesis defects in hyperthermia - Science Advances - January 3rd, 2020
- Rewriting Our Genes Is Easier Than Ever. That Doesn't Mean We Should Do It - WBUR - January 3rd, 2020
- Girl, 3, dies in her parents arms on New Years Day after leukaemia battle - The Sun - January 3rd, 2020
- Red Shamrock: Fight never over, even when kids beat cancer - Iowa City Press-Citizen - January 3rd, 2020
- International peace prize awarded to FNI executive director | Saginaw - Browncitybanner - January 3rd, 2020
- Scientists are Working on a Way to Regrow Teeth in 2 Months - Science Times - December 30th, 2019
- Stem Cell Assay Market Expected to Witness a Sustainable Growth over 2025 - Filmi Baba - December 30th, 2019
- The ethics of lab-grown "minibrains" - Quartz - December 30th, 2019
- What is HLH, and what role did it play in the death of a healthy 34-year-old ESPN reporter? - 11Alive.com WXIA - December 28th, 2019
- New technology being used to heal serious wounds - WWLTV.com - December 28th, 2019
- Five hot topics in autism research in 2019 - Spectrum - December 28th, 2019
- Humans may be Able to Regrow Teeth in the Future - NullTX - December 28th, 2019
- adult stem cells: the history of the research - December 22nd, 2019
- A New Gene Therapy Strategy, Courtesy of Mother Nature - Global Health News Wire - December 22nd, 2019
- GSK announces positive headline results in phase 3 study of Benlysta in patients with lupus nephritis | Antibodies | News Channels -... - December 21st, 2019
- Umbilical Cord Blood Banking Market to Achieve Massive Growth in the Near Future - Info Street Wire - December 21st, 2019
- Difference Between Adult and Embryonic Stem Cells | Compare ... - December 15th, 2019
- Science Fiction Becoming Reality - Reporter Magazine - December 15th, 2019
- Brenner and Rector's The Kidney, 2-Volume Set. Edition No. 11 - ResearchAndMarkets.com - Associated Press - December 6th, 2019
- Stem Cells Market to a Revenue Opportunity of US$270.5 bn During the Period from 2025 - News Description - December 6th, 2019
- Stem cell Therapy Market 2019-2027| Business Scope and Investment Analysis By MEDIPOST, PHARMICELL Co., Ltd, Holostem Terapie Avanzate Srl, Mesoblast... - December 6th, 2019
- Cutting Through the Headlines: Are Scientists Really Growing Sentient "Mini-brains"? - Technology Networks - December 6th, 2019
- Year in Review: Respiratory Infection - MedPage Today - December 6th, 2019
- Whats Happening: IDF Shabbat of Heroes, Sephardic Papers - Jewish Journal - December 5th, 2019
- Global Stem Cells Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Breaking News Updates - December 5th, 2019
- Marine Coatings Market is Anticipated to Register a Value of XX Million by the end of 2017 - 2025 - Markets Gazette 24 - December 5th, 2019
- Stem Cell Market 2019 | What Will Be the Market Size and the Growth Rate Analysis by 2026? - Hitz Dairies - December 3rd, 2019
- Stem Cells Market is Expected to Register a Healthy CAGR of 13.8% During the Period from 2017 to 2025 - Statsflash - December 3rd, 2019
- BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND - BioSpace - November 28th, 2019
- Inside the Beltway: Abortion, immigration among forbidden topics at Thanksgiving table - Washington Times - November 28th, 2019
- Canine Stem Cell Therapy Market Value Projected to Expand by 2026 - The Hilltop Monitor - November 28th, 2019
- Global Stem Cells Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Industry News Info - November 28th, 2019
- Stem Cell Banking Market Size, Share, Growth, Future Prospects, Competitive Analysis and Forecast To 2026 - Med News Ledger - November 28th, 2019
- Lulu and Nana are the result of a defiant experiment in human gene modification - The Irish Times - November 28th, 2019
- Types of Adult Stem Cells - Stem Cell Institute - November 26th, 2019
- Adult Leukemia: What You Need to Know - Dana-Farber Cancer Institute - November 26th, 2019
- Hatching disease in a dish: The new frontier in drug testing - Maclean's - November 26th, 2019
- Bedfordshire Police officer reunited with woman whose life he saved through stem cell donation - Bedford Today - November 26th, 2019
- BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND - GlobeNewswire - November 26th, 2019
- Bedfordshire Police officer reunited with stem cell recipient - Cranfield and Marston Vale Chronicle - November 26th, 2019
- Keeping cells alive | Interviews - The Naked Scientists - November 26th, 2019
- Dana-Farber joins with leading Boston teaching hospitals and universities - Mirage News - November 26th, 2019
- Applying AI and CRISPR to stem cells to improve regenerative medicine - FierceBiotech - November 20th, 2019
- Decoding the building blocks of life: bit bio races toward a sustainable source of human cells - Proactive Investors UK - November 20th, 2019
- 1st SCD Trial Patient Shows CTX001 Gene Editing to be Safe, Effective - Sickle Cell Anemia News - November 20th, 2019
- CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib - BioSpace - November 20th, 2019
- Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology - Arizona Daily Star - November 20th, 2019
- Maltese abroad: the best-selling author with roots in Gozo - Times of Malta - November 20th, 2019
- Early Results Are Positive for Experimental CRISPR Therapies - The Scientist - November 19th, 2019
- CHMP recommends EMA approval of polatuzumab vedotin for the treatment of adult patients with R/R DLBCL - Lymphoma Hub - November 19th, 2019
- CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib - PRNewswire - November 19th, 2019
- Redding woman donates bone marrow, saves life of a father - FOX61 Hartford - November 16th, 2019
- Maxim Group Maintains Their Buy Rating on Brainstorm Cell Therapeutics (BCLI) - Smarter Analyst - November 16th, 2019